Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 1Lymphoid 1

Conditions

Primary Myelofibrosis 4Myeloproliferative Disorders 4Carcinoma, Non-Small-Cell Lung 3Hematologic Neoplasms 2Thrombocytosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematologic Diseases 1

Interventions

Cyclophosphamide 53fludarabine phosphate 50Tacrolimus 41Busulfan 41Peripheral Blood Stem Cell Transplantation 37Mycophenolic Acid 36Whole-Body Irradiation 34Antilymphocyte Serum 34Cyclosporine 27Methotrexate 25fludarabine 24Melphalan 20Radiotherapy 19Filgrastim 16Methylprednisolone 14Cord Blood Stem Cell Transplantation 12Cytarabine 11thymoglobulin 10ruxolitinib 10Specimen Handling 10Biopsy 10Cyclosporins 9sargramostim 8Sirolimus 8Etoposide 8Alemtuzumab 8Thiotepa 7Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7Azacitidine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Myeloproliferative Disorders × INCB039110 × Clear all
NCT05364762 2026-06-03

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

City of Hope Medical Center

Phase 2 Active not recruiting
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT04629508 2025-09-02

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Incyte Corporation

Phase 2 Completed
4 enrolled 10 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT03144687 2022-06-16

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Incyte Corporation

Phase 2 Completed
23 enrolled 31 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT01633372 2021-08-30

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

Incyte Corporation

Phase 2 Completed
87 enrolled
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡